Abstract Coronavirus disease 2019 (COVID‐19) is still propagating a year after the start of
the pandemic. Besides the complications patients face during the COVID‐19 disease period …

Objective We sought to review the literature on cerebrospinal fluid (CSF) testing in patients
with COVID-19 for evidence of viral neuroinvasion by SARS-CoV-2. Methods We performed …

As the SARS-CoV-2 pandemic continues, reports have demonstrated neurologic sequelae
following COVID-19 recovery. Mechanisms to explain long-term neurological sequelae are …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. Although COVID-19 …

As cases of coronavirus disease 2019 (COVID-19) mount worldwide, attention is needed on
potential long-term neurologic impacts for the majority of patients who experience mild to …

Background and purpose Mounting evidence supports an association between Guillain−
Barré syndrome spectrum (GBSs) and severe acute respiratory syndrome coronavirus 2 …

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) predominantly
infects the respiratory system, several investigations have shown the involvement of the …

Background and purpose Neurological symptoms have been frequently reported in
hospitalized patients with coronavirus disease 2019 (COVID‐19), and biomarkers of central …

The advancing validation and exploitation of CSF and blood neurofilament light chain
protein as a biomarker of neuroaxonal damage has deeply changed the current diagnostic …

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a neurotropic
virus with a high neuroinvasive potential. Indeed, more than one-third of patients develop …